Получение рекомбинантного человеческого сывороточного альбумина в метилотрофных дрожжах Pichia pastoris
Sjoholm, I. and I. Ljungstedt, Studies on the tiyptophan and drug-binding properties of human serum albumin fragments by affinity chromatography and circular dichroism measurements. J Biol Chem, 1973. 248(24): p. 843 441. Rahman, M.H., et al., Study of interaction of carprofen and its enantiomers with human serum albumin—II. Stereoselective site-to-site displacement of carprofen by Ibuprofen… Читать ещё >
Получение рекомбинантного человеческого сывороточного альбумина в метилотрофных дрожжах Pichia pastoris (реферат, курсовая, диплом, контрольная)
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ОБЗОР ЛИТЕРАТУРЫ
- Синтез и структура человеческого сывороточного альбумина
- Свойства и функции ЧСА
- Связывание лигандов. ю
- Антгюксидантные свойства ЧСА
- Энзгтатические свойства ЧСА
- Области и стратегии применения препарата ЧСА
- Получение рекомбинантного ЧСА в различных системах экспрессии
- ЭкспрессиярЧСА в прокариотических системах Escherichia coli и Bacillus subtilis
- Экспрессия рЧСА в дрожэ/сах Saccharomyces cerevisiae
- Экспрессия рЧСА в дрожэ/сах Kluyveromyces lactis
- Экспрессия рЧСА в метилотрофных дролслсах Hansenula polymorpha (Pichia angusta)
- Система экспрессии рекомбинантных белков в метилотрофных дрожжах Pichia pastor is
- Преимущества системы экспрессии P. pastoris
- Генетические основы экспрессии белков дрожэ/сами P. pastoris
- Экспрессия рекомбинантного ЧСА в дрожэ/сах P. pastoris
- РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ
- Создание экспрессионного штамма GS115/ЧСА
- Подбор оптимальных условий аналитической экспрессии
- Оптимизация экспрессии целевого белка в условиях культивирования в ферментере
- Создание экспрессионного штамма GS115/ЧСА
- Очистка рЧСА из культуральной среды
- Структурно-функциональные исследования рЧСА
- Исследования биологической активности препарата рЧСА
- ВЫВОДЫ
- МАТЕРИАЛЫ И МЕТОДЫ
- Химические реактивы и сопутствующие материалы
- Методы работы с бактериями Esherichia col
- Методы работы с дрожжами Pichia pastoris
- Работа с нуклеиновыми кислотами
- Хроматографические процедуры
- Работа с белками
- Масс-спектрометрический анализ. юз
- Эксперименты с участием лабораторных животных. Ю
1. Peters T., J., All about Albumin: Biochemistry, Genetics, and Medical Applications. 1996, San Diego: Academic Press.
2. Sjoholm, I. and I. Ljungstedt, Studies on the tiyptophan and drug-binding properties of human serum albumin fragments by affinity chromatography and circular dichroism measurements. J Biol Chem, 1973. 248(24): p. 843 441.
3. Peters T., J., Serum albumin. In Advances in Protein Chemistry., ed. J.T.E. C. B. Anfinsen, F. Richards. 1985, New York: Academic Press.
4. Eckenhoff, R.G., et al., Inhaled anesthetic binding sites in human serum albumin. J Biol Chem, 2000. 275(39): p. 30 439−44.
5. Droge, W., Aging-related changes in the thiol/disidfide redox state: implications for the use of thiol antioxidants. Exp Gerontol, 2002. 37(12): p. 1333−45.
6. Nicholson, J.P., M.R. Wolmarans, and G.R. Park, The role of albumin in critical illness. Br J Anaesth, 2000. 85(4): p. 599−610.
7. Beeken, W.L., et al., Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest, 1962. 41: p. 1312−33.
8. Peters, T., Jr., Intracellular precursor forms of plasma proteins: their functions and possible occurrence in plasma. Clin Chem, 1987. 33(8): p. 1317−25.
9. Judah, J.D. and P. S. Quinn, Calcium ion-dependent vesicle fusion in the conversion ofproalbumin to albumin. Nature, 1978. 271(5643): p. 384−5.
10. Hawkins, J.W. and A. Dugaiczyk, The human serum albumin gene: structure of a unique locus. Gene, 1982. 19(1): p. 55−8.
11. Minghetti, P.P., et al., Molecular structure of the human albumin gene is revealed by nucleotide sequence within qll-22 of chromosome 4. J Biol Chem, 1986. 261(15): p. 6747−57.
12. Schell, L.M., et al., Distribution of albumin variants Naskapi amd Mexico among Aleuts, Frobisher Bay Eskimos, and Micmac, Naskapi, Mohawk, Omaha, and Apache Indians. Am J Phys Anthropol, 1978. 49(1): p. 111−7.
13. Arai, K., et al., Point substitutions in albumin genetic variants from Asia. Proc Natl Acad Sci USA, 1990. 87(1): p. 497−501.
14. Galliano, M., et al., Structural characterization of a chain termination mutant of human serum albumin. J Biol Chem, 1986. 261(9): p. 4283−7.
15. Minchiotti, L., et al., The molecidar defect in a COOH-terminal-modified and shortened mutant of human serum albumin. J Biol Chem, 1989. 264(6): p. 3385−9.
16. Brennan, S.O. and R.W. Carrell, A circulating variant of human proalbumin. Nature, 1978. 274(5674): p. 908−9.
17. Takahashi, N., et al., Amino acid substitutions in genetic variants of human serum albumin and in sequences inferred from molecular cloning. Proc Natl Acad Sci USA, 1987. 84(13): p. 4413−7.
18. Galliano, M., et al., A new proalbumin variant: albumin Jaffna (-1 Arg— Leu). FEBS Lett, 1989. 255(2): p. 295−9.
19. Abdo, Y., J. Rousseaux, and M. Dautrevaux, Proalbumin Lille, a new variant of human serum albumin. FEBS Lett, 1981. 131(2): p. 286−8.
20. Brennan, S.O., Propeptide cleavage: evidence from human proalbumins. Mol Biol Med, 1989. 6(1): p. 87−92.
21. Brennan, S.O., et al., Albumin Redhill (-1 Arg, 320 Ala—Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site. Proc Natl Acad Sci USA, 1990. 87(1): p. 26−30.
22. Weil, M.H., R.J. Henning, and V.K. Puri, Colloid oncotic pressure: clinical significance. Crit Care Med, 1979. 7(3): p. 113−6.
23. Воробьев, А.И., Проблемы гематол. и перелив, крови., 1999(2): р. 5.
24. Городецкий, В.М., Гематол. и трансфузиол., 1994(3): р. 25.
25. Sudlow, G., D.J. Birkett, and D.N. Wade, The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol, 1975. 11(6): p. 824−32.
26. Yamasaki, K., et al., Characterization of site I on human serum albumin: concept about the sti-ucture of a drug binding site. Biochim Biophys Acta, 1996.1295(2): p. 147−57.
27. Kragh-Hansen, U., Octanoate binding to the indoleand benzodiazepine-binding region of human serum albumin. Biochem J, 1991. 273 (Pt 3): p. 641−4.
28. Kragh-Hansen, U., Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol Pharmacol, 1988. 34(2): p. 160−71.
29. Rahman, M.H., et al., Characterization of high affinity binding sites of nonsteroidal anti-inflammatoiy drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull, 1993. 16(11): p. 1169−74.
30. Meisner, H. and K. Neet, Competitive binding of long-chain free fatty acids, octanoate, arid chlorophenoxyisobutyrate to albumin. Mol Pharmacol, 1978. 14(2): p. 337−46.
31. Kragh-Hansen, U., Molecular aspects of ligand binding to serum albumin. Pharmacol Rev, 1981. 33(1): p. 17−53.
32. Montero, M.T., et al., On the binding of cinmetacin and indomethacin to human serum albumin. J Pharm Pharmacol, 1986. 38(12): p. 925−7.
33. Otagiri, M., et al., Binding of pirprofen to human serum albumin studied by dialysis and spectroscopy techniques. Biochem Pharmacol, 1989. 38(1): p. 17.
34. Valiner, J.J., Binding of drugs by albumin and plasma protein. J Pharm Sei, 1977. 66(4): p. 447−65.
35. Bischer, A., et al., Stereoselective binding properties of naproxen glucuronide diastereomers to proteins. J Pharmacokinet Biopharm, 1995. 23(4): p. 37 995.
36. Bertucci, C., et al., Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal, 1998.18(1−2): p. 127−36.
37. Otagiri, M., et al., Characterization of binding sites for sidfadimethoxine and its major metabolite, N4-acetylsulfadimethoxine, on human and rabbit serum albumin. Chem Pharm Bull (Tokyo), 1989. 37(2): p. 498−501.
38. Yamasaki, K., et al., Circular dichroism simidation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by Ibuprofen. AAPS PharmSciTech, 2000.1(2): p. E12.
39. Takamura, N., et al., Interaction of benzothiadiazides with human serum albumin studied by dialysis and spectroscopic methods. Pharm Res, 1994. 11(10): p. 1452−7.
40. Takamura, N., et al., Mode of interaction of loop diuretics with human serum albumin and characterization of binding site. Pharm Res, 1996. 13(7): p. 1015−9.
41. Mignot, I., et al., Albumin binding sites for etodolac enantiomers. Chirality, 1996. 8(3): p. 271−80.
42. Boulton, D.W., U.K. Walle, and T. Walle, Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol, 1998. 50(2): p. 243−9.
43. Rahman, M.H., et al., Study of interaction of carprofen and its enantiomers with human serum albumin—II. Stereoselective site-to-site displacement of carprofen by Ibuprofen. Biochem Pharmacol, 1993. 46(10): p. 1733−40.
44. Bree, F., et al., Nimesulide binding to components within blood. Drugs, 1993. 46 Suppl 1: p. 83−90.
45. Sueyasu, M., et al., Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg, 2000. 91(3): p. 736−40.
46. Sugio, S., et al., Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng, 1999. 12(6): p. 439−46.
47. He, X.M. and D.C. Carter, Atomic structure and chemistiy of human serum albumin. Nature, 1992. 358(6383): p. 209−15.
48. Petitpas, I., et al., Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem, 2001. 276(25): p. 22 804−9.4950,5152,53,54.55,56.